Ki-67/MIB-1 as a Prognostic Marker in Cervical Cancer - a Systematic Review with Meta-Analysis

  • Piri, Reza (Medical Philosophy and History Research Center, Tabriz University of Medical Sciences) ;
  • Ghaffari, Alireza (Medical Philosophy and History Research Center, Tabriz University of Medical Sciences) ;
  • Gholami, Nasrin (Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Azami-Aghdash, Saber (Health Management and Economics Research Center, Iran University of medical sciences) ;
  • PourAli-Akbar, Yasmin (Students' Research Committee, Tabriz University of Medical Sciences) ;
  • Saleh, Parviz (Chronic Kidney Diseases Research Center, Tabriz University of Medical Sciences) ;
  • Naghavi-Behzad, Mohammad (Students' Research Committee, Tabriz University of Medical Sciences)
  • Published : 2015.11.04


Background: In cervical cancer patients it has been reported that there in a significant Ki-67/MIB-1 expression is correlated with survival in cervical cancer patients. However, the prognostic value is still not well understood. Materials and Methods: In the present meta-analysis the prognostic value of Ki-67/MIB-1 with regard to overall survival (OS) and disease-free survival (DFS) in cervical cancer was investigated. The databases of PubMed, ISI Web of Science, Cochrane Central Register of Controlled Trials, EMBASE, Science Direct and Wiley Online Library were used to identify appropriate literature. Results: In order to explore the relationship between Ki-67/MIB-1 and cervical cancer, we have included 13 studies covering 894 patients in the current meta-analysis. The effect of Ki-67/MIB-1 on OS for pooled random effects HR estimate was 1.63 (95%confidence interval (CI) 1.09-2.45; P<0.05). The pooled HR for DFS was 1.26 (95%CI 0.58-2.73; P>0.05) and the subgroup analysis indicated Ki-67/MIB1 was associated with DFS (HR=3.67, 95%CI 2.65-5.09) in Asians. Conclusions: According to this meta-analysis, Ki-67/MIB-1 has prognostic value for OS in patients suffering from cervical cancer. For better evaluation of the prognostic role of Ki-67/MIB-1 on DFS, studies with larger numbers of patients are needed to validate present findings in the future.


Cervical cancer;Ki-67/MIB-1;prognosis;meta-analysis


  1. Aliasgarzadeh A, Ghojazadeh M, Haji-Hoseini R, et al (2014). Age related secretary pattern of growth hormone, insulinlike growth factor-I & insulin-like growth factor binding protein-3 in postmenopausal women. Indian J Med Res, 139, 598-602.
  2. Altman DG, Lausen B, Sauerbrei W, et al (1994). Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst, 86, 829-35.
  3. Amirnia M, Babaie-Ghazani A, Fakhrjou A, et al (2014). Immunohistochemical study of cyclooxygenase-2 in skin tumors. J Dermatolog Treat, 25, 380-7.
  4. Andrae B, Andersson TM, Lambert PC, et al (2012). Screening and cervical cancer cure: population based cohort study. Bmj, 344.
  5. Azami-Aghdash S, Ghaffari S, Sadeghi-Bazargani H, et al (2013). Developing Indicators of Service Quality Provided for CardiovascularPatients Hospitalized in Cardiac Care Unit. J Cardiovascular Thoracic Res, 5, 23.
  6. Azami-Aghdash S, Ghojazadeh M, Pournaghi Azar F, et al (2013). Fluoride concentration of drinking waters and prevalence of fluorosis in iran: a systematic review. J Dent Res Dent Clin Dent Prospects, 7, 1-7.
  7. Bahnassy AA, Zekri AR, Alam El-Din HM, et al (2006). The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. J Egypt Natl Canc Inst, 18, 292-302.
  8. Bahnassy AA, Zekri AR, Saleh M, et al (2007). The possible role of cell cycle regulators in multistep process of HPVassociated cervical carcinoma. BMC Clin Pathol, 7, 4.
  9. Battista MJ, Mantai N, Sicking I, et al (2014). Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: Results of an explorative, retrospective study. Oncol Reports, 31, 2213-9.
  10. Chaturvedi AK, Engels EA, Pfeiffer RM, et al (2011). Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol, 29, 4294-301.
  11. Costa S, Terzano P, Santini D, et al (2001). Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol, 116, 729-37.
  12. Cserni G, Voros A, Liepniece-Karele I, et al (2014). Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast, 23, 259-63.
  13. de Azambuja E, Cardoso F, de Castro G, Jr, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13.
  14. Eskander RN, Tewari KS (2014). Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol, 25, 249-59.
  15. Fakhrjou A, Dastranj-Tabrizi A, Ghojazadeh M, et al (2013). Diagnostic value of protein Ki67 (MIB-1) in atypical pap smears of postmenopausal women. Asian Pac J Cancer Prev, 14, 4815-8.
  16. Fasanella S, Leonardi E, Cantaloni C, et al (2011). Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol, 6, 7.
  17. Ghojazadeh M, Azar ZF, Saleh P, et al (2012a). Knowledge and attitude of Iranian university students toward human papilloma virus. Asian Pac J Cancer Prev, 13, 6115-9.
  18. Ghojazadeh M, Mohammadi M, Azami-Aghdash S, et al (2013). Estimation of cancer cases using capture-recapture method in Northwest Iran. Asian Pac J Cancer Prev, 14, 3237-41.
  19. Ghojazadeh M, Naghavi-Behzad M, Azar ZF, et al (2012b). Parental knowledge and attitudes about human papilloma virus in Iran. Asian Pac J Cancer Prev, 13, 6169-73.
  20. Ghojazadeh M, Naghavi-Behzad M, Nasrolah-Zadeh R, et al (2014). Knowledge production status of Iranian researchers in the gastric cancer area: based on the medline database. Asian Pac J Cancer Prev, 15, 5083-8.
  21. Goldhirsch A, Winer E, Coates A, et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 24, 2206-23.
  22. Graflund M, Sorbe B, Karlsson M (2002). MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome. Int J Oncol, 20, 1041-7.
  23. Ho DM, Hsu CY, Chiang H (2000). MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol, 76, 97-102.
  24. Hu Y, Correa AM, Hoque A, et al (2011). Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer, 128, 132-43.
  25. Ikenberg H, Bergeron C, Schmidt D, et al (2013). Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst, 105, 1550-7.
  26. Jabbari H, Alikhah H, Alamdari NS, et al (2012). Developing the use of quality indicators in sterilization practices. Iranian J Health, 41, 64.
  27. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. Ca Cancer J Clin, 61, 69-90.
  28. Karami H, Baradaran B, Esfahani A, et al (2013). siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev, 14, 7719-24.
  29. Keam B, Im S-A, Lee K-H, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, 22.
  30. Kesic V, Poljak M, Rogovskaya S (2012). Cervical cancer burden and prevention activities in Europe. Cancer Epidemiol Biomarkers Prev, 21, 1423-33.
  31. Klimek M, Kruczak A, Rys J, et al (2011). Clinico-morphological parameters affecting survival of patients with advanced cervical cancer. Pol J Pathol, 62, 250-6.
  32. Lindboe CF, Torp SH (2002). Comparison of Ki-67 equivalent antibodies. J Clin Pathol, 55, 467-71.
  33. Lindboe CF, von der Ohe G, Torp SH (2003). Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies. APMIS, 111, 567-70.
  34. Mohammadzadeh M, Pourzand A, Eftekhar-Sadat AT, et al (2013). A case of concurrent several forms of thyroid cancer. Niger Med J, 54, 351-3.
  35. Naghavi-Behzad M, Alizadeh M, Azami S, et al (2013). Risk Factors of Congenital Heart Diseases: Case-Control Study in Northwest Iran. J Cardiovascular Thoracic Rese, 5, 5.
  36. Oka K, Suzuki Y, Nakano T (2000). High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma. Cancer, 89, 1526-31.<1526::AID-CNCR16>3.0.CO;2-2
  37. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.<2815::AID-SIM110>3.0.CO;2-8
  38. Peng Y, Wang L, Gu J (2013). Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J Surg, 37, 208-13.
  39. Rahimi-Ardabili B, Argani H, Ghorbanihaghjo A, et al (2012). Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients. Renal Failure, 34, 1123-8.
  40. Rostamizadeh L, Fakhrjou A, Montazeri V, et al (2013). Bcl-2 gene expression in human breast cancers in iran. Asian Pac J Cancer Prev, 14, 4209-14.
  41. Shams-Vahdati S, Vand-Rajavpour Z, Paknezhad S-P, et al (2014). Cost-effectiveness of cardiac biomarkers as screening test in acute chest pain. J Cardiovasc Thoracic Res, 6, 29.
  42. Shiohara S, Shiozawa T, Miyamoto T, et al (2005). Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch, 446, 626-33.
  43. Smith SJ, Tilly H, Ward JH, et al (2012). CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol, 124, 99-110.
  44. Spyratos F, Ferrero-Pous M, Trassard M, et al (2002). Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer, 94, 2151-9.
  45. Sugino T, Baba K, Hoshi N, et al (2011). Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. Med Mol Morphol, 44, 146-50.
  46. Sultana H, Kigawa J, Kanamori Y, et al (2003). Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol, 14, 214-9.
  47. Sushma M, Vamsikrishna B, Babu M, et al (2014). A review on role of human papilomma virus (HPV) in cervical cancer. PharmaTutor, 2, 21-30.
  48. Suzuki M, Tsukagoshi S, Saga Y, et al (2000). Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer. Gynecol Oncol, 79, 300-4.
  49. Tollefson MK, Karnes RJ, Kwon ED, et al (2014). Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the mayo model. Mayo Clinic Proc, 89, 308-18.
  50. Van de Putte G, Kristensen GB, Lie AK, et al (2004). Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol, 92, 40-6.
  51. Walts AE, Ines D, Marchevsky AM (2012). Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol, 25, 1258-64.
  52. Wang M-J, Pei D-S, Qian G-W, et al (2011). p53 regulates Ki-67 promoter activity through p53-and Sp1-dependent manner in HeLa cells. Tumor Biol, 32, 905-12.
  53. Warth A, Cortis J, Soltermann A, et al (2014). Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer, 111, 1222-9.
  54. Yaghoubi A, Tabrizi JS, Mirinazhad MM, et al (2012). Quality of life in cardiovascular patients in Iran and factors affecting it: A systematic review. J Cardiovascular Thoracic Res, 4, 95.
  55. Yang M, Liu YD, Wang YY, et al (2014). Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biol, 35, 929-34.
  56. Yusuf S, Peto R, Lewis J, et al (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 27, 335-71.
  57. Zhang T, Zhao C, Chen D, et al (2012a). Overexpression of AQP5 in cervical cancer: correlation with clinicopathological features and prognosis. Med Oncol, 29, 1998-2004.
  58. Zhang T, Zhao C, Luo L, et al (2012b). The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol, 29, 1985-91.